A drug development company working on a drug for Alzheimer's Disease and other forms of dementia. More generally, Appia is focused on the development of drugs modulating epigenetic mechanisms. It's lead compound appears to reverse certain abnormal epigenetic modification patterns found in neurodegenerative diseases such as Alzheimer's; it is an orally bioavailable HAT activator with unique pharmacological and safety profiles that has shown efficacy in mouse models.